Numerous epidemiological studies have been conducted demonstrating that a high intake of isoflavones has bone-sparing effects. Research suggests that genistein exerts its effect by managing the metabolic imbalance in bone tissue induced by ovarian hormone depletion, an important fact because the primary type of osteoporosis affects postmenopausal women. Genistein is a phytoestrogen that acts as a mild SERM (selective estrogen receptor modulator) that can upregulate bone cell metabolism without serious side effects.